SNC-102 (Shanghai Simnova Biotechnology)

N/A

Report date: 2025/05/13 15:10:28

Base Information

Drug NameSNC-102 (Shanghai Simnova Biotechnology)
Drug Alias NameCART-BCMASNC102
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived
Mechanisms of ActionB-cell maturation protein modulators
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Simnova Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Simnova Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A